Podium Presentations
Monday, 31 October 2016
11:15 - 12:15
BREAKOUT SESSION

11:15 - 12:15
Room: Hall F2 (L0)
P1: MODELING METHODS
Moderator: Matthew Taylor, MSc, PhD
Director, York Health Economics Consortium, York, UK

MO1

11:15 - 11:30

WITHDRAWN

MO2

11:15 - 11:30

CONSIDERING OR NOT ADVERSE EVENTS IN HEALTH ECONOMIC MODELS: A PRAGMATIC APPROACH

Roze S, Cartier-Bechu C, Gherardi A, Monnier R, Pignata M, Petijean A, Sivignon M
HEVA HEOR Sarl, Lyon, France

MO3

11:30 - 11:45

THE IMPACT OF DYNAMIC TRANSMISSION MODELLING ON THE ESTIMATED COST-EFFECTIVENESS OF TREATMENT FOR CHRONIC HEPATITIS C IN THE UNITED KINGDOM

Madin-Warburton M1, Pitcher A1, Martin N2
1IMS Health, London, UK, 2University of California San Diego, San Diego, CA, USA

MO4

11:45 - 12:00

THE IMPACT OF EXTRAPOLATING SURVIVAL BASED ON CURE MODELS: COMPARING MEAN INCREMENTAL SURVIVAL AND CURE RATES IN DIFFERENT DATASETS

van Oostrum I1, Postma MJ2, Buskens E3, Heeg BM1
1Ingress-health Netherlands, Rotterdam, The Netherlands, 2University of Groningen, Groningen, The Netherlands, 3University Medical Center Groningen, Groningen, The Netherlands
14:15 - 15:15
BREAKOUT SESSION

14:15 - 15:15
Room: Hall F1 (L0)
P2: STUDIES ON HTA APPROACHES
Moderator: Gerry Oster, PhD bio
Managing Partner, Policy Analysis Inc. (PAI), Brookline, MA, USA

HT1

14:15 - 14:30

ALIGNED AND FLEXIBLE? A COMPARATIVE REVIEW OF SMC AND NICE DECISION-MAKING

Johnson H1, Spoors J2, Johnson J1
1Helen Johnson Consulting Ltd, Welwyn Garden City, UK, 2RJW & Partners, Royston, UK

HT2

14:30 - 14:45

A REVIEW OF THE USE OF NETWORK META-ANALYSIS IN NICE SINGLE TECHNOLOGY APPRAISALS

Fleetwood K1, Glanville J2, McCool R2, Wood H2, Wilson K2, Marshall C2, Yellowlees A1, James D1, Toupin S1, McCabe R1
1Quantics Consulting Ltd, Edinburgh, UK, 2York Health Economics Consortium Ltd, York, UK

HT3

14:45 - 15:00

ACTUARIAL APPROACHES TO MODELLING AND MITIGATING FINANCIAL UNCERTAINTY IN RECOMMENDING NEW HEALTH TECHNOLOGIES

Serre D, Buckle J
Milliman, London, UK

HT4

15:00 - 15:15

IMPLEMENTATION OF CONDITIONAL REIMBURSEMENT SCHEMES IN HTA PRACTICE: EXPERIENCES FROM THE NETHERLANDS

Makady A1, Nijmeijer H2, de Boer A3, Hillege JL4, Klungel O5, Goettsch W1
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2Radboud University Medical Centre, Nijmegen, The Netherlands, 3Utrecht University, Utrecht, The Netherlands, 4University Medical Center Groningen, Groningen, The Netherlands, 5Utrecht University, UTRECHT, The Netherlands

14:15 - 15:15
Room: Hall F2 (L0)
P3: UTILITY STUDIES
Moderator: Ursula Rochau, Ass.-Prof., MD, MSc
Assistant Professor, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health, Health Services Research and HTA/ ONCOTYROL - Center for Personalized Medicine, Hall i.T./ Innsbruck, Austria

UT1

14:15 - 14:30

UTILITY BY TREATMENT LINE IN MULTIPLE MYELOMA; ANALYSIS OF OVER 9000 EQ-5Q-3L QUESTIONNAIRES FROM THE EMMOS REGISTRY

Hatswell AJ1, Couturier C2, Ito T3
1BresMed, Sheffield, UK, 2Janssen Medical Affairs, Paris, France, 3Janssen Health Economics & Market Access EMEA, High Wycombe, UK

UT2

14:30 - 14:45

A META REGRESSION ANALYSIS OF UTILITY WEIGHTS FOR BREAST CANCER

Gong JR, Lim J, Bae S
Ewha Womans University, Seoul, South Korea

UT3

14:45 - 15:00

PROSPECTIVE UTILITY STUDY OF PATIENTS WITH MULTIPLE CARDIOVASCULAR EVENTS

Pockett RD1, McEwan P2, Ray J3, Tran I4, Shutler S5, Martin S6, Yousef Z7, Bakhai A8
1Swansea University, Swansea, UK, 2Health Economics and Outcomes Research Ltd, Cardiff, UK, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Roche Products Ltd, Welwyn Garden City, UK, 5F. Hoffmann-La Roche Ltd., Basel, Switzerland, 6Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, UK, 7University Hospital of Wales, Cardiff, UK, 8Royal Free London NHS Foundation Trust, Barnet, UK

UT4

15:00 - 15:15

MAPPING QUALITY OF LIFE SCORES FROM FACT-G, FAACT AND FACIT-F ONTO PREFERENCE-BASED UTILITIES USING THE 5-LEVEL VERSION OF EQ-5D QUESTIONNAIRE

Meregaglia M1, Borsoi L1, Cairns J2, Tarricone R1
1Bocconi University, Milan, Italy, 2London School of Hygiene and Tropical Medicine, London, UK
15:45 - 16:45
BREAKOUT SESSION

15:45 - 16:45
Room: Hall F1 (L0)
P4: CARDIOVASCULAR OUTCOMES RESEARCH STUDIES
Moderator: Daniel Gladwell
Principal Consultant, BresMed, Sheffield, UK

CV4

16:30 - 16:45

ARE COMPONENT ENDPOINTS EQUAL? A STUDY INTO THE PRACTICE OF COMPOSITE END POINTS IN CLINICAL TRIALS

Vaanholt MC1, von Birgelen C2, Kok M3, Weernink MG1, van Til J2
1University Twente, Enschede, The Netherlands, 2University of Twente, Enschede, The Netherlands, 3Medisch Spectrum Twente, Enschede, The Netherlands

CV1

15:45 - 16:00

COMPARISON OF ORAL ANTI-COAGULANTS FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION: TWO MULTI-CRITERIA DECISION ANALYSES

Tervonen T1, Ustyugova AV2, Lip G3, Verdecchia P4, Sri Bhashyam S1, Heinrich-Nols J5, Gropper S5, Kwan R6, Marsh K1
1Evidera Ltd, London, UK, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 3University of Birmingham, Birmingham, UK, 4Hospital of Assisi, Assisi, Italy, 5Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, 6Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada

CV2

16:00 - 16:15

USING SUBPOPULATION TREATMENT EFFECT PATTERN PLOT TO IDENTIFY MORE EFFICIENT RESOURCE ALLOCATION POLICIES

Cao Q1, Hillege JL2, Postma MJ2, Buskens E2, Postmus D3
1University of Groningen, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, The Netherlands, 3University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

CV3

16:15 - 16:30

POLICY OBJECTIVE OF GENERIC MEDICINES FROM THE INVESTMENT PERSPECTIVE: THE CASE OF CLOPIDOGREL

Elek P1, Harsányi A2, Zelei T3, Csetneki K3, Kaló Z3
1Eötvös Loránd University (ELTE), Budapest, Hungary, 2Eötvös Loránd University, Budapest, Hungary, 3Syreon Research Institute, Budapest, Hungary

15:45 - 16:45
Room: Hall F2 (L0)
P5: PRICING POLICY STUDIES
Moderator: Mitja Kos, PhD
Associate Professor, Chair of Social Pharmacy, University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia

PR1

15:45 - 16:00

ASSOCIATION BETWEEN THE PRICES OF ORPHAN DRUGS IN ONCOLOGY AND THE PATIENT POPULATION SIZES

Jarosławski S, Toumi M
Aix-Marseille University, Marseille, France

PR2

16:00 - 16:15

PAY FOR PERFORMANCE: A PROPOSAL FOR AND SIMULATION OF REAL TIME OUTCOMES-BASED PHARMACEUTICAL PRICING USING ROUTINELY COLLECTED DATA

Butt T1, Lee A2, Tufail A3
1University College London, London, UK, 2University of Washington, Seattle, WA, USA, 3Moorfields Eye Hospital NHS Foundation Trust, London, UK

PR3

16:15 - 16:30

DIFFERENCES IN PRICING POLICIES FOR GENERIC AND BIOSIMILAR MEDICINES

Vogler S, Schneider P, Gombocz M, Zimmermann N
Gesundheit Österreich GmbH / Austrian Public Health Institute, Vienna, Austria

PR4

16:30 - 16:45

THE DETERMINANTS OF INNOVATIVE DRUGS PRICES: THE CASE OF ONCOLOGY DRUGS, COMPARATIVE ANALYSIS

Aissaoui A1, Levy P2
1Paris Dauphine University, PSL, Paris, France, 2Université Paris-Dauphine, Paris, France
17:00 - 18:00
BREAKOUT SESSION

17:00 - 18:00
Room: Hall F1 (L0)
P6: MEDICATION ADHERENCE STUDIES
Moderator: Lorenzo G. Mantovani
Professor (Associate), Public Health, Department of Statistics and Quantitative Methods, School of Medicine, University of Milano-Bicocca, Monza, Italy

AD1

17:00 - 17:15

REAL-WORLD IMPACT OF GENDER, AGE AND SOCIO-ECONOMIC STATUS ON TYPE-2 DIABETES MELLITUS (T2DM) PATIENTS DISEASE ENGAGEMENT AND ADHERENCE WITH TREATMENT REGIMENS

Higgins V, Leith A, Benford M, Siddall J, Piercy J
Adelphi Real World, Bollington, UK

AD2

17:15 - 17:30

A FRAMEWORK FOR MEASURING ADHERENCE TO MULTIPLE MEDICATIONS

Pednekar P1, Agh T2, Raval A3, Malmenäs M4, Peterson AM5, Bennett B6, Abrahamyan L7, Bunz TJ2, Borah BJ8, Hutchinson D9, Hiligsmann M10, Manias E11, Williams A12, Turcu-Stiolica A13, Zeber J14
1University of the Sciences, Philadelphia, PA, USA, 2Syreon Research Institute, Budapest, Hungary, 3Healthcore, Inc., Wilmington, DE, USA, 4PAREXEL International, Stockholm, Sweden, 5University of the Sciences in Philadelphia, Philadelphia, PA, USA, 6Adelphi Values Ltd, Bollington, UK, 7University of Toronto, Toronto, ON, Canada, 8Mayo Clinic College of Medicine, Rochester, MN, USA, 9Pharmacy Networks, CVS Caremark, Scottsdale, AZ, USA, 10Maastricht University, Maastricht, The Netherlands, 11Deakin University, Burwood, Australia, 12Monash University, Clayton, Australia, 13Faculty of Pharmacy, University of Medicine and Pharmacy, Craiova, Romania, 14Center for Applied Health Research, Temple, TX, USA

AD3

17:30 - 17:45

MEDICATION ADHERENCE AND PERSISTANCE IN TYPE 2 DIABETES MELLITUS (T2DM): PATIENTS PERSPECTIVE IN THE SPANISH HEALTH CARE SYSTEM

Labrador Barba E1, Hernandez Mijares A2, Alonso Moreno FJ3, Rodriguez de Miguel M1, Orera Peña ML1, Aceituno Mata S4, Perez L4, Faus Dader MJ5
1Mylan, Barcelona, Spain, 2Dr. Peset Hospital, Valencia, Spain, 3Sillería Health Center, Toledo, Spain, 4Outcomes’10, Castellon, Spain, 5Faculty of Pharmacy, Granada, Spain

AD4

17:45 - 18:00

ADHERENCE TO TREATMENT AND MODIFIABLE RISK FACTORS IN ACUTE CORONARY SYNDROME (ACS) PATIENTS REGISTERED IN THE PGRX REAL WORLD DATASETS

Cuervo J1, Nordon C2, Rossignol M3, Morisot N2, Benichou J4, Danchin N5, Abenhaim L6, Grimaldi-Bensouda L2
1HEOR, Oviedo, Spain, 2LASER Analytica, Paris, France, 3McGill University, Montreal, QC, Canada, 4Centre Hospitalier Universitaire de Rouen, Paris, France, 5Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, 6LASER Analytica, London, UK
Tuesday, 1 November 2016
8:45 - 9:45
BREAKOUT SESSION

8:45 - 9:45
Room: Hall F1 (L0)
P7: NEUROLOGICAL DISORDERS STUDIES
Moderator: Paolo Angelo Cortesi, PhD
Researcher, Research Centre on Public Health (CESP), University of Milano-Bicocca, Monza, Italy

ND1

8:45 - 9:00

BURDEN AND WORK PRODUCTIVITY LOSS IMPAIRMENT FROM PROVIDING CARE TO ALZHEIMER'S DISEASE PATIENTS

Hu X1, Ritchie C2, Wood R3, Jones E3, Black CM4, Khandker RK4, Ambegaonkar BM4
1University of Southern California, Los Angeles, CA, USA, 2University of Edinburgh, Edinburgh, UK, 3Adelphi Real World, Bollington, UK, 4Merck & Co., Inc., Rahway, NJ, USA

ND2

9:00 - 9:15

ADVANCED PARKINSON’S DISEASE IN STOCKHOLM COUNTY, SWEDEN – HOW MANY ARE THEY AND WHAT ARE THE REAL-LIFE HEALTH CARE COSTS?

Eriksson JK1, Anell B2
1Karolinska Institute, Stockholm, Sweden, 2Parexel International, Stockholm, Sweden

ND3

9:15 - 9:30

THE COST OF MULTIPLE SCLEROSIS IN 16 EUROPEAN COUNTRIES: FUNCTIONAL STATUS, SYMPTOMS AND MENTAL FACTORS DRIVE COSTS

Berg J1, Gannedahl M1, Capsa D1, Eriksson J2, Thompson A3, Kobelt G4
1Mapi, Stockholm, Sweden, 2Mapi Group, Stockholm, Sweden, 3University College London, London, UK, 4European Health Economics, Mulhouse, France

ND4

9:30 - 9:45

EXCESS COSTS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA IN THE ELDERLY

Menzin J, Park SS
Boston Health Economics, Waltham, MA, USA

8:45 - 9:45
Room: Hall F2 (L0)
P8: PATIENT PREFERENCE STUDIES
Moderator: Andrew J. Lloyd, DPhil
VP (Practice Lead), Patient Reported Outcomes, Oxford Outcomes, An ICON plc Company, Oxford, UK

PP1

8:45 - 9:00

NINE TESTS FOR ASSESING VALIDITY OF A DISCRETE-CHOICE EXPERIMENT

Janssen EM, Bridges JF
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PP2

9:00 - 9:15

HETEROGENEOUS PREFERENCES FOR DELAYING ONSET OF ALZHEIMER’S DISEASE AMONG OLDER ADULTS IN THE US

Reed SD1, Yang J1, Disantostefano R2, Streffer J3, Levitan B2, Johnson FR1
1Duke Clinical Research Institute, Durham, NC, USA, 2Janssen R&D, Titusville, NJ, USA, 3Janssen R&D, Beerse, Belgium

PP3

9:15 - 9:30

PATIENTS' PREFERENCES FOR CHARACTERISTICS OF PERIODONTAL DISEASE AND ITS' TREATMENT: A DISCRETE CHOICE EXPERIMENT

Vennedey V1, Danner M1, Civello D1, Schwalm A2, Seidl A2, Hiligsmann M3, Stock S1
1University Hospital Cologne, Cologne, Germany, 2Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 3Maastricht University, Maastricht, The Netherlands

PP4

9:30 - 9:45

COMPARING PREFERENCES OF PATIENTS WITH RHEUMATIC DISEASES, OF EXPERIENCED RHEUMATOLOGISTS, NURSES AND PHARMACISTS TOWARD THE TREATMENT OF RHEUMATIC DISEASES WITH BIOLOGICAL AGENTS: RESULTS FROM THE CARA STUDY

Scalone L1, Cortesi PA1, Sarzi-Puttini P2, Sinigaglia L3, Montecucco C4, Giacomelli R5, Lapadula G6, Olivieri I7, Giardino AM8, Mecchia M8, Mantovani LG1
1University of Milano-Bicocca, Monza, Italy, 2Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, 3Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, 4University of Pavia, Pavia, Italy, 5University of L'Aquila, L'Aquila, Italy, 6University of Bari, Bari, Italy, 7Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera, Italy, 8MSD Italy, Rome, Italy
13:45 - 14:45
BREAKOUT SESSION

13:45 - 14:45
Room: Hall F2 (L0)
P9: ECONOMIC EVALUATION STUDIES
Moderator: Adam Hutchings, MSc
Director, Dolon Ltd, London, UK

EE1

13:45 - 14:00

ECONOMIC EVALUATION FOR THE UNITED KINGDOM OF SYSTEMIC CHEMOTHERAPIES AS FIRST-LINE TREATMENT FOR METASTATIC PANCREATIC CANCER

Gharaibeh M1, McBride A2, Alberts D2, Slack M1, Erstad B1, Abraham I1
1University of Arizona, Tucson, AZ, USA, 2Arizona Cancer Center, Tucson, AZ, USA

EE2

14:00 - 14:15

IS IT REALLY COST-EFFECTIVE TO RISK-ASSESS ALL HOSPITALIZED PATIENTS FOR PRESSURE ULCERS EVERY NURSING-SHIFT?

Padula WV1, Onyekwere U1, Makic MB2, Wald HL2, Epstein Z3, Meltzer DO4
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2University of Colorado, Aurora, CO, USA, 3Pomona College, Claremont, CA, USA, 4University of Chicago, Chicago, IL, USA

EE3

14:15 - 14:30

THE COST-EFFECTIVENESS OF BARIATRIC SURGERY IN GERMANY, FRANCE, ITALY AND THE UNITED KINGDOM

Belarbi S1, Kusel J2, Thomas MG2
1Ethicon SAS, Issy-Les-Moulineaux, France, 2Costello Medical Consulting Ltd, Cambridge, UK

EE4

14:30 - 14:45

COST EFFECTIVENESS OF NIVOLUMAB MONOTHERAPY FOR THE TREATMENT OF ADVANCED MELANOMA PATIENTS IN THE UNITED KINGDOM

Meng Y1, Hertel N2, Ellis J2, Johnson H3, Philips Z1, Roskell N1, Lee D1
1BresMed Health Solutions, Sheffield, UK, 2Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK, 3Helen Johnson Consulting Ltd, Welwyn Garden City, UK

13:45 - 14:45
Room: Hall F1 (L0)
P10: HTA & VALUE ASSESSMENT STUDIES
Moderator: Petra Schnell-Inderst, MPH, Dipl. Biol
Senior Scientist, Head, Program on Health Technology Assessment Institute of Public Health, Medical Decision Making and Health Technology Assessment Dept. of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria

HT5

13:45 - 14:00

DEVELOPMENT OF A MULTI-CRITERIA DECISION ANALYSIS (MCDA) FRAMEWORK FOR HEALTH CARE DECISION-MAKING IN CATALONIA (SPAIN): PILOT STUDY FOCUSED IN ORPHAN DRUGS

Gilabert-Perramon A1, Torrent-Farnell J2, Catalan A3, Prat A4, Fontanet M2, Puig-Peiró R5, Merino-Montero S6, Khoury H7, Goetghebeur MM8, Badia X6
1Catalan Health Service, Government of Catalonia, Barcelona, Spain, 2Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 3Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Barcelona, Spain, 4Servei Català de la Salut (CatSalut), Barcelona, Spain, 5Catalan Health Service (CatSalut), Barcelona, Spain, 6Omakase Consulting, Barcelona, Spain, 7LASER Analytica, Montreal, QC, Canada, 8LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada

HT6

14:00 - 14:15

CRITERIA DRIVING VALUES ASSESSMENTS IN MULTIPLE SCLEROSIS MEDICINES

Visintin E1, Kanavos P2
1London School of Economics and Political Sciences, London, UK, 2London School of Economics and Political Science, London, UK

HT7

14:15 - 14:30

HTA AGENCIES PERSPECTIVE ON PROGRESSION-FREE-SURVIVAL (PFS)

Schmitter S1, Holzerny P2, Brock E2, Günzel C3, Ruckdäschel S2
1Pfizer Deutschland GmbH, Berlin, Germany, 2HealthEcon AG, Basel, Switzerland, 3Pfizer Pharma GmbH, Berlin, Germany

HT8

14:30 - 14:45

DEFINING THE VALUE: DO THE NEW ONCOLOGY FRAMEWORKS IN THE US AIM AT OBJECTIVE VALUATION? – A CASE STUDY IN MULTIPLE MYELOMA

Forsythe A1, Pezalla EJ2
1PS HTA, New York, NY, USA, 2Enlightenment BioConsult, LLC., Wethersfield, CT, USA
15:15 - 16:15
BREAKOUT SESSION

15:15 - 16:15
Room: Hall D (L -2)
P11: DATABASE USE IN OUTCOMES RESEARCH STUDIES
Moderator: Joseph E. Biskupiak, PhD, MBA
Research Professor, Pharmacotherapy, University of Utah, Salt Lake City, UT, USA

DB1

15:15 - 15:30

MORTALITY EXCESS DUE TO CLOSTRIDIUM DIFFICILE INFECTION - A NATIONAL DATABASE ANALYSIS

Bouee S1, Levy Bachelot L2, Ravonimbola H2, Longepierre L1, Godard C2, Gourmelen J3, Barbut F4
1CEMKA, Bourg La Reine, France, 2MSD France, Courbevoie, France, 3UMS 011 - Inserm - UVSQ, Villejuif, France, 4Laboratory for Clostridium Difficile, Paris, France

DB2

15:30 - 15:45

A RETROSPECTIVE STUDY ON ASSOCIATION BETWEEN CHANGE IN BMI AND INCIDENCE OF HYPERTENSION USING A HEALTH CARE DATABASE IN JAPAN

Yamamoto Y1, Tanabe K2, Takahashi S2, Ii Y2, Kitazaki S1, Fujimoto Y2
1MinaCare Co. Ltd, Tokyo, Japan, 2Pfizer Japan Inc, Tokyo, Japan

DB3

15:45 - 16:00

ACCURACY OF NATURAL LANGUAGE PROCESSING-BASED CLASSIFIERS FOR AUTOMATED IDENTIFICATION OF ABSTRACTS OF STUDIES ON HUMANISTIC AND ECONOMIC BURDEN OF DISEASE

Krohn J1, Martin A2, Martin C2
1Krohn Consulting Ltd, Coventry, UK, 2Crystallise Ltd., London, UK

DB4

16:00 - 16:15

USE OF DATA-MINING TO PERFORM A REAL WORLD COST ANALYSIS OF HER2-POSITIVE BREAST CANCER IN IRAN

Ansaripour A1, Zendehdel K2, Tadayon N3, Sadeghi F4, Uyl-de Groot C5, Redekop WK6
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Tehran Medical Sciences and Medical Education University, Tehran, Iran, 3Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of), 4Tehran Medical Sciences and Medical education University, Tehran, Iran, 5National Health Care Institute, Diemen, The Netherlands, 6National University of Singapore, Singapore, Singapore

15:15 - 16:15
Room: Hall F2 (L0)
P12: HEALTH CARE EXPENDITURE & REIMBURSEMENT STUDIES
Moderator: Jeanette Kusel, MSci, MSc
Head of HTA and Health Economics, Costello Medical Consulting Ltd, Cambridge, UK

HC1

15:15 - 15:30

MODELING THE IMPACT OF REFORM TO THE CANCER DRUGS FUND

Karlsberg Schaffer S, Garau M, O'Neill P, Bianchi S
Office of Health Economics, London, UK

HC2

15:30 - 15:45

ECONOMIC BURDEN OF DISEASES IN FRANCE: ANALYSING THE TRENDS FROM 2012 TO 2014, USING THE FRENCH HEALTH INSURANCE DATABASE (SNIIRAM)

Gastaldi Menager C1, Drouin J2, Pestel L3, Fagot-Campagna A2, Gissot C3
1CNAMTS, Paris, France, 2CNAMTS (National Health Insurance), Paris Cedex 20, France, 3CNAMTS (National Health Insurance), Paris, France

HC3

15:45 - 16:00

THE RELATIONSHIP BETWEEN MEDICAL INNOVATION AND HEALTH EXPENDITURES

Cinaroglu S1, Guzel E2, Baser O3
1Hacettepe University, Ankara, Turkey, 2Eastern Michigan University, Ypsilanti, MI, USA, 3Columbia University/MEF University/STATinMED Research, New York, NY, USA

HC4

16:00 - 16:15

COMPARISON OF TIME TO REIMBURSEMENT DECISION OF INNOVATIVE PHARMACEUTICALS IN EUROPE

Hernandez J, Nientker K, Hensen M
Pharmerit International, Rotterdam, The Netherlands
16:30 - 17:30
BREAKOUT SESSION

16:30 - 17:30
Room: Hall F2 (L0)
P13: MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES
Moderator: Rok Hren, PhD, MSc IHP(HE)
Assistant Professor, University of Ljubljana, Ljubljana, Slovenia

MD1

16:30 - 16:45

MEDICAL DEVICES: TIMELY ACCESS AND REIMBURSEMENT - CAN NATIONAL HEALTH TECHNOLOGY ASSESSMENT BODIES BE PART OF THE SOLUTION?

Macaulay R, Shaw S
Parexel Access Consulting, London, UK

MD2

16:45 - 17:00

TOWARDS IMPROVED CERVICAL CANCER PRIMARY SCREENING IN AUSTRIA - A DECISION-ANALYTIC BENEFIT-HARM ANALYSIS

Sroczynski G1, Esteban E1, Widschwendter A2, Oberaigner W3, Borena W2, von Laer D2, Hackl M4, Endel G5, Siebert U6
1UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL - Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria, 2Medical University Innsbruck, Innsbruck, Austria, 3Tirol Kliniken Innsbruck, Innsbruck, Austria, 4Statistics Austria, Austrian National Cancer Registry, Directorate Social Statistics, Statistics Austria, Vienna, Austria, 5Main Association of Austrian Social Insurance Institutions, Vienna, Austria, 6and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria

MD3

17:00 - 17:15

ADOPTION OF TRANSCATHETER MITRAL VALVE REPAIR IN GERMANY: UTILIZATION PATTERNS AND CASE VOLUMES COMPARED TO MITRAL VALVE SURGERY IN THE PERIOD 2010-2014

Pietzsch JB1, Weber SA2, Pietzsch ML2, Conradi L3
1Wing Tech Inc., Irvine, CA, USA, 2Cellogic GmbH, Berlin, Germany, 3University Heart Center Hamburg, Hamburg, Germany

MD4

17:15 - 17:30

DECISION UNCERTAINTY AND THE NEED FOR FURTHER RESEARCH: A CASE STUDY IN FENESTRATED ENDOVASCULAR ANEURYSM REPAIR FOR COMPLEX ABDOMINAL AORTIC ANEURYSMS

Ciani O1, Epstein D2, Rothery C3, Taylor RS1, Sculpher M3
1University of Exeter Medical School, Exeter, UK, 2University of Granada, Granada, Spain, 3University of York, Heslington, York, UK
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.